Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report

Background: We have previously reported a high incidence of colorectal cancer (CRC) in carriers of pathogenic MLH1 variants (path_MLH1) despite follow-up with colonoscopy including polypectomy. Methods: The cohort included Finnish carriers enrolled in 3-yearly colonoscopy (n = 505; 4625 observation years) and carriers from other countries enrolled in colonoscopy 2-yearly or more frequently (n = 439; 3299 observation years). We examined whether the longer interval between colonoscopies in Finland could explain the high incidence of CRC and whether disease expression correlated with differences in population CRC incidence. Results: Cumulative CRC incidences in carriers of path_MLH1 at 70-years of age were 41% for males and 36% for females in the Finnish series and 58% and 55% in the non-Finnish series, respectively (p > 0.05). Mean time from last colonoscopy to CRC was 32.7 months in the Finnish compared to 31.0 months in the non-Finnish (p > 0.05) and was therefore unaffected by the recommended colonoscopy interval. Differences in population incidence of CRC could not explain the lower point estimates for CRC in the Finnish series. Ten-year overall survival after CRC was similar for the Finnish and non-Finnish series (88% and 91%, respectively; p > 0.05). (Continued on next page) * Correspondence: toni.seppala@fimnet.fi; toni.t.seppala@hus.fi Department of Surgery, Helsinki University Hospital and University of Helsinki, Post Box 340, 00029 Helsinki, Finland Finnish Lynch Syndrome registry, Helsinki University Hospital, Helsinki, Finland Full list of author information is available at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Seppälä et al. Hereditary Cancer in Clinical Practice (2017) 15:18 DOI 10.1186/s13053-017-0078-5

[1]  M. Kloor,et al.  CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome , 2016, Familial Cancer.

[2]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[3]  C. Rubio,et al.  Colonoscopy findings in high-risk individuals compared to an average-risk control population , 2015, Scandinavian journal of gastroenterology.

[4]  F. Lalloo,et al.  Colonoscopy screening compliance and outcomes in patients with Lynch syndrome , 2015, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[5]  A. Lindblom,et al.  A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer , 2014, International journal of cancer.

[6]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[7]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[8]  M. Woods,et al.  Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation , 2012, Clinical genetics.

[9]  Axel Benner,et al.  Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. , 2012, The Lancet. Oncology.

[10]  E. Dekker,et al.  One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. , 2010, Gastroenterology.

[11]  M. Kloor,et al.  Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Jukka-Pekka Mecklin,et al.  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Ramesar,et al.  Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[14]  Esa Läärä,et al.  Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. , 2007, Gastroenterology.

[15]  M. Kloor,et al.  Beta2‐microglobulin mutations in microsatellite unstable colorectal tumors , 2007, International journal of cancer.

[16]  P. Møller,et al.  Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer , 2007, Scandinavian journal of gastroenterology.

[17]  S. Bojesen,et al.  Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer , 2007, International Journal of Technology Assessment in Health Care.

[18]  J. Mecklin,et al.  Compliance and Satisfaction with Long-Term Surveillance in Finnish HNPCC Families , 2005, Familial Cancer.

[19]  Joanna Adams,et al.  Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study , 2005, BMJ : British Medical Journal.

[20]  M. von Knebel Doeberitz,et al.  Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Eilers,et al.  The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. , 2004, Gastroenterology.

[22]  J. Kleibeuker,et al.  Surveillance for Hereditary Nonpolyposis Colorectal Cancer: A Long-Term Study on 114 Families , 2002, Diseases of the colon and rectum.

[23]  E. Jaramillo,et al.  Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer , 2002, Gut.

[24]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[25]  P. Radice,et al.  Survival of patients with hereditary colorectal cancer: Comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer , 1999, International journal of cancer.

[26]  F. Nagengast,et al.  Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome) , 1995, The Lancet.